Brand new flavor of Seroxat/Paxil called PEXEVA.

[Guest guest]

http://home.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view & ne\

wsId=20040318005098 & newsLang=en

March 18, 2004 06:00 AM US Eastern Timezone

Synthon's PEXEVA Brings Big Savings To SSRI Market; Bold Business Model Quickly

Differentiating the Company

CHAPEL HILL, N.C.--(BUSINESS WIRE)--March 18, 2004--Synthon Pharmaceuticals,

Ltd. today announced that it has launched PEXEVA (paroxetine as mesylate) 10

mg, 20 mg, 30 mg, and 40 mg tablets for the treatment of depression,

obsessive/compulsive disorder and/or panic disorder. Synthon's PEXEVA is an

alternative for patients in need of, or currently undergoing, selective

serotonin reuptake inhibitor (SSRI) therapy.

PEXEVA is the first product launched by Synthon in the U.S. under a new,

revolutionary business model. The company's model brings high quality, branded

pharmaceutical alternatives to the U.S. market at significant discounts when

compared to market leaders. The company's strength is pharmaceutical chemistry

which allows them to develop alternatives to existing therapies, patent their

discoveries and offer them to the medical community at steep discounts. At the

same time, Synthon will offer many of the support mechanisms traditionally

offered by the industry including sales force support, samples, medical

information, etc.

PEXEVA is aggressively priced and supported by a national sales team and a team

of managed care professionals working to educate physicians, consumers and

payers about the benefits of the drug and potential consumer savings. " This is

great news for those patients currently taking an SSRI to treat their

depression, panic disorder or obsessive/compulsive disorder. PEXEVA provides

physicians, pharmacists, and most importantly, patients, with a branded, safe,

effective and more affordable alternative to other SSRI therapies. We will

endeavor to bring products in other therapeutic areas to market using the same

business model--brand products at the lowest possible prices, " said Dr.

J. , President of Synthon Pharmaceuticals, Ltd.

Synthon's PEXEVA is a brand product composed of paroxetine mesylate. PEXEVA is

bioequivalent to GlaxoKline's Paxil®(1), which is composed of paroxetine

hydrochloride. The chemical difference between the two products is the inactive

salt portion of the active ingredient (PEXEVA's mesylate vs. PAXIL's

hydrochloride). The inactive salt is separated from the active paroxetine

molecule in the gastrointestinal tract, leaving only the active paroxetine

molecule to be absorbed into the bloodstream and provide the intended

therapeutic effect.

Synthon's initial marketing of PEXEVA entails a multi-year agreement with Ventiv

Health Inc., a Somerset, N.J. based sales and marketing firm. Synthon has also

contracted with VCG & A, a respected managed markets consulting firm, to provide

corporate and field-based support with various payers.

" Synthon has crafted a business model that delivers what healthcare consumers

have been asking for, particularly those consumers who require pharmaceutical

therapies to maintain their health or quality of life, " noted D. Shales,

Vice President of Sales & Marketing at Synthon. " Our plan is to build a

full-service commercial organization. Ventiv and VCG & A give us the resources to

tell our story while we build our infrastructure. We believe our growth will be

rapid, " Mr. Shales added.

European clinicians have used Synthon's paroxetine mesylate with confidence for

over three years, with more than 60 million tablets sold. The result has been

considerable savings for European consumers.

" We are selling PEXEVA into the trade at roughly a 31% discount to Paxil(2). We

are providing consumers and other payers the chance to vote with their

pocketbooks: they can continue the status quo, or they can obtain significant

savings in this important and growing market by using PEXEVA. Last year,

spending in the U.S. paroxetine market totaled $2.7 billion and the SSRI / SNRI

market totaled $10.6 billion(3). Our market research clearly indicates that

patients and the medical community want a reasonably priced SSRI product, and

that's exactly what Synthon is delivering, " Dr. stated.

" Our business model is different and, quite frankly, exciting, " concluded Mr.

Shales. " With the reception we've received in the SSRI market with PEXEVA, our

pipeline and the team we are building, we think Synthon is well positioned in

the evolving healthcare industry. "

The Synthon family of companies discovers, develops and markets both active

pharmaceutical ingredients and finished pharmaceutical dosage forms. The

companies market a broad therapeutic portfolio of 56 products in more than 38

countries around the world. The Synthon family of companies is renowned for

successful drug discovery, quality products, excellent drug submissions,

innovative analysis and quality control testing.

(1)Paxil is a registered trademark of GlaxoKline

(2)Source: First Databank, March 5 2004

(3) NDC Health Pharmaceutical Audit, 2003

Jim - Norman

" Never look at the trombones, it only encourages them. "

Strauss

[Guest guest]

http://home.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view & ne\

wsId=20040318005098 & newsLang=en

March 18, 2004 06:00 AM US Eastern Timezone

Synthon's PEXEVA Brings Big Savings To SSRI Market; Bold Business Model Quickly

Differentiating the Company

CHAPEL HILL, N.C.--(BUSINESS WIRE)--March 18, 2004--Synthon Pharmaceuticals,

Ltd. today announced that it has launched PEXEVA (paroxetine as mesylate) 10

mg, 20 mg, 30 mg, and 40 mg tablets for the treatment of depression,

obsessive/compulsive disorder and/or panic disorder. Synthon's PEXEVA is an

alternative for patients in need of, or currently undergoing, selective

serotonin reuptake inhibitor (SSRI) therapy.

PEXEVA is the first product launched by Synthon in the U.S. under a new,

revolutionary business model. The company's model brings high quality, branded

pharmaceutical alternatives to the U.S. market at significant discounts when

compared to market leaders. The company's strength is pharmaceutical chemistry

which allows them to develop alternatives to existing therapies, patent their

discoveries and offer them to the medical community at steep discounts. At the

same time, Synthon will offer many of the support mechanisms traditionally

offered by the industry including sales force support, samples, medical

information, etc.

PEXEVA is aggressively priced and supported by a national sales team and a team

of managed care professionals working to educate physicians, consumers and

payers about the benefits of the drug and potential consumer savings. " This is

great news for those patients currently taking an SSRI to treat their

depression, panic disorder or obsessive/compulsive disorder. PEXEVA provides

physicians, pharmacists, and most importantly, patients, with a branded, safe,

effective and more affordable alternative to other SSRI therapies. We will

endeavor to bring products in other therapeutic areas to market using the same

business model--brand products at the lowest possible prices, " said Dr.

J. , President of Synthon Pharmaceuticals, Ltd.

Synthon's PEXEVA is a brand product composed of paroxetine mesylate. PEXEVA is

bioequivalent to GlaxoKline's Paxil®(1), which is composed of paroxetine

hydrochloride. The chemical difference between the two products is the inactive

salt portion of the active ingredient (PEXEVA's mesylate vs. PAXIL's

hydrochloride). The inactive salt is separated from the active paroxetine

molecule in the gastrointestinal tract, leaving only the active paroxetine

molecule to be absorbed into the bloodstream and provide the intended

therapeutic effect.

Synthon's initial marketing of PEXEVA entails a multi-year agreement with Ventiv

Health Inc., a Somerset, N.J. based sales and marketing firm. Synthon has also

contracted with VCG & A, a respected managed markets consulting firm, to provide

corporate and field-based support with various payers.

" Synthon has crafted a business model that delivers what healthcare consumers

have been asking for, particularly those consumers who require pharmaceutical

therapies to maintain their health or quality of life, " noted D. Shales,

Vice President of Sales & Marketing at Synthon. " Our plan is to build a

full-service commercial organization. Ventiv and VCG & A give us the resources to

tell our story while we build our infrastructure. We believe our growth will be

rapid, " Mr. Shales added.

European clinicians have used Synthon's paroxetine mesylate with confidence for

over three years, with more than 60 million tablets sold. The result has been

considerable savings for European consumers.

" We are selling PEXEVA into the trade at roughly a 31% discount to Paxil(2). We

are providing consumers and other payers the chance to vote with their

pocketbooks: they can continue the status quo, or they can obtain significant

savings in this important and growing market by using PEXEVA. Last year,

spending in the U.S. paroxetine market totaled $2.7 billion and the SSRI / SNRI

market totaled $10.6 billion(3). Our market research clearly indicates that

patients and the medical community want a reasonably priced SSRI product, and

that's exactly what Synthon is delivering, " Dr. stated.

" Our business model is different and, quite frankly, exciting, " concluded Mr.

Shales. " With the reception we've received in the SSRI market with PEXEVA, our

pipeline and the team we are building, we think Synthon is well positioned in

the evolving healthcare industry. "

The Synthon family of companies discovers, develops and markets both active

pharmaceutical ingredients and finished pharmaceutical dosage forms. The

companies market a broad therapeutic portfolio of 56 products in more than 38

countries around the world. The Synthon family of companies is renowned for

successful drug discovery, quality products, excellent drug submissions,

innovative analysis and quality control testing.

(1)Paxil is a registered trademark of GlaxoKline

(2)Source: First Databank, March 5 2004

(3) NDC Health Pharmaceutical Audit, 2003

Jim - Norman

" Never look at the trombones, it only encourages them. "

Strauss

[Guest guest]

http://home.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view & ne\

wsId=20040318005098 & newsLang=en

March 18, 2004 06:00 AM US Eastern Timezone

Synthon's PEXEVA Brings Big Savings To SSRI Market; Bold Business Model Quickly

Differentiating the Company

CHAPEL HILL, N.C.--(BUSINESS WIRE)--March 18, 2004--Synthon Pharmaceuticals,

Ltd. today announced that it has launched PEXEVA (paroxetine as mesylate) 10

mg, 20 mg, 30 mg, and 40 mg tablets for the treatment of depression,

obsessive/compulsive disorder and/or panic disorder. Synthon's PEXEVA is an

alternative for patients in need of, or currently undergoing, selective

serotonin reuptake inhibitor (SSRI) therapy.

PEXEVA is the first product launched by Synthon in the U.S. under a new,

revolutionary business model. The company's model brings high quality, branded

pharmaceutical alternatives to the U.S. market at significant discounts when

compared to market leaders. The company's strength is pharmaceutical chemistry

which allows them to develop alternatives to existing therapies, patent their

discoveries and offer them to the medical community at steep discounts. At the

same time, Synthon will offer many of the support mechanisms traditionally

offered by the industry including sales force support, samples, medical

information, etc.

PEXEVA is aggressively priced and supported by a national sales team and a team

of managed care professionals working to educate physicians, consumers and

payers about the benefits of the drug and potential consumer savings. " This is

great news for those patients currently taking an SSRI to treat their

depression, panic disorder or obsessive/compulsive disorder. PEXEVA provides

physicians, pharmacists, and most importantly, patients, with a branded, safe,

effective and more affordable alternative to other SSRI therapies. We will

endeavor to bring products in other therapeutic areas to market using the same

business model--brand products at the lowest possible prices, " said Dr.

J. , President of Synthon Pharmaceuticals, Ltd.

Synthon's PEXEVA is a brand product composed of paroxetine mesylate. PEXEVA is

bioequivalent to GlaxoKline's Paxil®(1), which is composed of paroxetine

hydrochloride. The chemical difference between the two products is the inactive

salt portion of the active ingredient (PEXEVA's mesylate vs. PAXIL's

hydrochloride). The inactive salt is separated from the active paroxetine

molecule in the gastrointestinal tract, leaving only the active paroxetine

molecule to be absorbed into the bloodstream and provide the intended

therapeutic effect.

Synthon's initial marketing of PEXEVA entails a multi-year agreement with Ventiv

Health Inc., a Somerset, N.J. based sales and marketing firm. Synthon has also

contracted with VCG & A, a respected managed markets consulting firm, to provide

corporate and field-based support with various payers.

" Synthon has crafted a business model that delivers what healthcare consumers

have been asking for, particularly those consumers who require pharmaceutical

therapies to maintain their health or quality of life, " noted D. Shales,

Vice President of Sales & Marketing at Synthon. " Our plan is to build a

full-service commercial organization. Ventiv and VCG & A give us the resources to

tell our story while we build our infrastructure. We believe our growth will be

rapid, " Mr. Shales added.

European clinicians have used Synthon's paroxetine mesylate with confidence for

over three years, with more than 60 million tablets sold. The result has been

considerable savings for European consumers.

" We are selling PEXEVA into the trade at roughly a 31% discount to Paxil(2). We

are providing consumers and other payers the chance to vote with their

pocketbooks: they can continue the status quo, or they can obtain significant

savings in this important and growing market by using PEXEVA. Last year,

spending in the U.S. paroxetine market totaled $2.7 billion and the SSRI / SNRI

market totaled $10.6 billion(3). Our market research clearly indicates that

patients and the medical community want a reasonably priced SSRI product, and

that's exactly what Synthon is delivering, " Dr. stated.

" Our business model is different and, quite frankly, exciting, " concluded Mr.

Shales. " With the reception we've received in the SSRI market with PEXEVA, our

pipeline and the team we are building, we think Synthon is well positioned in

the evolving healthcare industry. "

The Synthon family of companies discovers, develops and markets both active

pharmaceutical ingredients and finished pharmaceutical dosage forms. The

companies market a broad therapeutic portfolio of 56 products in more than 38

countries around the world. The Synthon family of companies is renowned for

successful drug discovery, quality products, excellent drug submissions,

innovative analysis and quality control testing.

(1)Paxil is a registered trademark of GlaxoKline

(2)Source: First Databank, March 5 2004

(3) NDC Health Pharmaceutical Audit, 2003

Jim - Norman

" Never look at the trombones, it only encourages them. "

Strauss

[Guest guest]

http://home.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view & ne\

wsId=20040318005098 & newsLang=en

March 18, 2004 06:00 AM US Eastern Timezone

Synthon's PEXEVA Brings Big Savings To SSRI Market; Bold Business Model Quickly

Differentiating the Company

CHAPEL HILL, N.C.--(BUSINESS WIRE)--March 18, 2004--Synthon Pharmaceuticals,

Ltd. today announced that it has launched PEXEVA (paroxetine as mesylate) 10

mg, 20 mg, 30 mg, and 40 mg tablets for the treatment of depression,

obsessive/compulsive disorder and/or panic disorder. Synthon's PEXEVA is an

alternative for patients in need of, or currently undergoing, selective

serotonin reuptake inhibitor (SSRI) therapy.

PEXEVA is the first product launched by Synthon in the U.S. under a new,

revolutionary business model. The company's model brings high quality, branded

pharmaceutical alternatives to the U.S. market at significant discounts when

compared to market leaders. The company's strength is pharmaceutical chemistry

which allows them to develop alternatives to existing therapies, patent their

discoveries and offer them to the medical community at steep discounts. At the

same time, Synthon will offer many of the support mechanisms traditionally

offered by the industry including sales force support, samples, medical

information, etc.

PEXEVA is aggressively priced and supported by a national sales team and a team

of managed care professionals working to educate physicians, consumers and

payers about the benefits of the drug and potential consumer savings. " This is

great news for those patients currently taking an SSRI to treat their

depression, panic disorder or obsessive/compulsive disorder. PEXEVA provides

physicians, pharmacists, and most importantly, patients, with a branded, safe,

effective and more affordable alternative to other SSRI therapies. We will

endeavor to bring products in other therapeutic areas to market using the same

business model--brand products at the lowest possible prices, " said Dr.

J. , President of Synthon Pharmaceuticals, Ltd.

Synthon's PEXEVA is a brand product composed of paroxetine mesylate. PEXEVA is

bioequivalent to GlaxoKline's Paxil®(1), which is composed of paroxetine

hydrochloride. The chemical difference between the two products is the inactive

salt portion of the active ingredient (PEXEVA's mesylate vs. PAXIL's

hydrochloride). The inactive salt is separated from the active paroxetine

molecule in the gastrointestinal tract, leaving only the active paroxetine

molecule to be absorbed into the bloodstream and provide the intended

therapeutic effect.

Synthon's initial marketing of PEXEVA entails a multi-year agreement with Ventiv

Health Inc., a Somerset, N.J. based sales and marketing firm. Synthon has also

contracted with VCG & A, a respected managed markets consulting firm, to provide

corporate and field-based support with various payers.

" Synthon has crafted a business model that delivers what healthcare consumers

have been asking for, particularly those consumers who require pharmaceutical

therapies to maintain their health or quality of life, " noted D. Shales,

Vice President of Sales & Marketing at Synthon. " Our plan is to build a

full-service commercial organization. Ventiv and VCG & A give us the resources to

tell our story while we build our infrastructure. We believe our growth will be

rapid, " Mr. Shales added.

European clinicians have used Synthon's paroxetine mesylate with confidence for

over three years, with more than 60 million tablets sold. The result has been

considerable savings for European consumers.

" We are selling PEXEVA into the trade at roughly a 31% discount to Paxil(2). We

are providing consumers and other payers the chance to vote with their

pocketbooks: they can continue the status quo, or they can obtain significant

savings in this important and growing market by using PEXEVA. Last year,

spending in the U.S. paroxetine market totaled $2.7 billion and the SSRI / SNRI

market totaled $10.6 billion(3). Our market research clearly indicates that

patients and the medical community want a reasonably priced SSRI product, and

that's exactly what Synthon is delivering, " Dr. stated.

" Our business model is different and, quite frankly, exciting, " concluded Mr.

Shales. " With the reception we've received in the SSRI market with PEXEVA, our

pipeline and the team we are building, we think Synthon is well positioned in

the evolving healthcare industry. "

The Synthon family of companies discovers, develops and markets both active

pharmaceutical ingredients and finished pharmaceutical dosage forms. The

companies market a broad therapeutic portfolio of 56 products in more than 38

countries around the world. The Synthon family of companies is renowned for

successful drug discovery, quality products, excellent drug submissions,

innovative analysis and quality control testing.

(1)Paxil is a registered trademark of GlaxoKline

(2)Source: First Databank, March 5 2004

(3) NDC Health Pharmaceutical Audit, 2003

Jim - Norman

" Never look at the trombones, it only encourages them. "

Strauss